| Nov 7 |
Context Therapeutics GAAP EPS of -$0.22
|
| Nov 6 |
Context Therapeutics files for $250M mixed securities shelf
|
| Nov 6 |
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
|
| Oct 23 |
Context Therapeutics to Participate in Upcoming Investor Conferences in November
|
| Oct 16 |
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
|
| Sep 23 |
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
|
| Sep 16 |
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
|
| Sep 4 |
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
|
| Aug 27 |
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
|
| Aug 8 |
Context Therapeutics GAAP EPS of -$0.04
|
